Mountain Vy Md Stock Price, News & Analysis

Mountain Valley MD Holdings Inc. (trading over-the-counter under the symbol MVMDF) is a biotechnology-focused company centered on the implementation, licensing, and reselling of key health and agricultural technologies and formulations. Across its disclosures, the company describes three core business lines: nutraceuticals powered by its patented Quicksome™ oral formulation and delivery technologies, husbandry animal and aquatic applications using its patented Quicksol™ solubility formulation technology, and agricultural solutions as a licensed product reseller of Agrarius™, a plant signaling technology designed to support crop performance.

Core Technologies and Business Model

Mountain Valley MD states that it is building its organization around owned and licensed technologies that can be implemented, licensed, and resold rather than relying on in-house large-scale manufacturing. In its public updates, the company highlights three primary technology pillars:

• Quicksome™ oral formulation and delivery technologies – patented liposomal formulations and stabilizing molecules intended to encapsulate active ingredients and optimize delivery in sublingual nutraceutical formats. The company describes Quicksome™ as focusing on applications where enhanced efficacy, precise dosing, reduced variability, and dose sparing are valued.
• Quicksol™ solubility formulation technology – a patented technology covering highly solubilized macrocyclic lactones, which the company indicates can be applied to drug formulations such as ivermectin. Mountain Valley MD reports that Quicksol™-based formulations are designed to improve solubility, bioavailability, and stability for human and animal health applications.
• Agrarius™ agricultural plant signaling technology – a licensed, certified organic product that the company describes as a plant signaling technology applied to crops to naturally increase yields, reduce fertilizer usage where desired, and enhance resilience to pests and climate-related stress.

According to multiple company news releases, Mountain Valley MD’s business activities emphasize implementation and licensing of these platforms to partners, along with reselling of licensed agricultural products within defined territories.

Nutraceuticals and Quicksome™ Platform

In its nutraceutical line of business, Mountain Valley MD reports that its Quicksome™ technology is used to formulate sublingual rapid-dissolve tablets and powders. The company describes Quicksome™ as using proprietary formulations and stabilizing agents to encapsulate active ingredients, with the goal of delivering molecules into the body faster and with greater impact and efficiency than conventional orally consumed products.

The company has disclosed a licensing and manufacturing structure in which a U.S.-based GMP production partner (referred to as the “Lead Manufacturer”) produces Quicksome™-based nutraceutical products for Mountain Valley MD licensees and for the company’s proprietary “Mountains Of…” brand. Public updates describe the following elements of its nutraceutical activities:

• Application of Quicksome™ technology to functional mushroom-based sublingual products under a license agreement with Circadian Wellness Corp., including products such as Eons Deeper Sleep and Eons Dialed, which the company states incorporate Quicksome™ technology.
• Development of additional Quicksome™ formulations for categories such as sleep, energy, immunity, appetite suppressant, lean metabolism, focus, stress and anxiety support, joint health, pain management, hematological health, nutritional support, hydration and performance.
• Use of Quicksome™ in proprietary formulations for specific client projects, including a fenugreek glycosides testosterone formulation and an opioid use disorder adjunct therapy project, as described in company business updates.

Mountain Valley MD reports that its “Mountains Of…” brand has obtained trademark protection in the United States for multiple product categories, including Sleep, Energy, Relief, Libido, and Lean, and that these formulations are available to distribution partners either under the company’s brand or as white-label products manufactured by its Lead Manufacturer.

Quicksol™ Technology and Soluvec™ 1%

In the husbandry animals and aquatic species segment, Mountain Valley MD describes applying its Quicksol™ technology to ivermectin to create a formulation referred to as Soluvec™ 1%. The company states that this formulation is designed to provide a safer and more effective solution for administration across husbandry animals and aquatic species, and that third-party validation has demonstrated stability at room and refrigerated temperatures.

Public disclosures indicate that the company’s commercialization strategy for Soluvec™ 1% is based on licensing the technology to regional partners rather than directly operating manufacturing facilities. For example, Mountain Valley MD reports an exclusive license agreement with a partner in Bangladesh to manufacture and distribute Soluvec™ 1% products in injectable and feed coating formats in exchange for royalties based on net sales. The company has also stated that it is exploring additional licensing opportunities in Latin America and other markets and has filed for patent protection for Soluvec™ in multiple jurisdictions outside the United States.

According to the company, peer-reviewed study data published in the journal Therapeutic Delivery support improved bioavailability, efficacy, and potential cost savings of Soluvec™ formulations compared to conventional ivermectin formulations.

Agrarius™ Agricultural Plant Signaling Technology

Mountain Valley MD’s agricultural business is centered on its role as a licensed reseller and exclusive distributor of the Agrarius™ plant signaling technology in specified territories. Under an Amended and Restated Supply and License Agreement with Agrarius Corp., the company reports holding exclusive rights to sell Agrarius™ in North America, Mexico, Central America, South America, and the Caribbean, while retaining non-exclusive rights outside this territory.

The company describes Agrarius™ as a certified organic product designed to activate plant defense mechanisms at the cellular level without the actual stress factor, with intended effects that include deeper root growth, optimized photosynthesis, improved water and nutrient use efficiency, and increased resistance to diseases and climate stress. Across multiple news releases, Mountain Valley MD reports that Agrarius™ has been tested across numerous crops and has demonstrated:

• Natural yield increases, with reported ranges that vary by crop and trial.
• Potential reductions in fertilizer usage where applied.
• Improved resilience to pests and environmental stress, including drought conditions.

The company highlights extensive trial programs in Latin America, including citrus, corn, sugarcane, soybeans, cotton, potatoes, and pasture grass, undertaken with third-party agronomy partners, universities, farmer networks, and agricultural organizations. It also reports a Performance Guarantee Program under which participating clients pay for Agrarius™ only if agreed performance thresholds are met, with Mountain Valley MD and Agrarius Corp. sharing the performance risk.

Vision and Application Areas

Mountain Valley MD repeatedly references a vision of “More Life” in its public communications. It states that it applies its technologies to advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and related wellness areas. In agriculture, the company positions its work with Agrarius™ as focused on generating positive impacts on crop yields and reducing fertilizer usage.

Across its lines of business, the company emphasizes licensing arrangements, trademarked brands, and partnerships with manufacturing, agronomy, and distribution partners as central to its operating approach.

Trading and Industry Context

Mountain Valley MD Holdings Inc. is referenced in public news as trading on the CSE under the symbol MVMD and on the OTCQB under the symbol MVMDF, with an additional listing reference on the FRA under the symbol 20MP. While the initial classification provided lists the industry as gold ore mining, the company’s own disclosures consistently describe its activities in biotechnology-related nutraceuticals, pharmaceutical formulation technologies, and agricultural plant signaling products rather than mineral extraction.

FAQs

• What does Mountain Valley MD Holdings Inc. do?
  Mountain Valley MD Holdings Inc. focuses on implementing, licensing, and reselling health and agricultural technologies. Its primary platforms include Quicksome™ oral formulation and delivery technologies, Quicksol™ solubility formulation technology, and the licensed Agrarius™ agricultural plant signaling technology.
• How does Mountain Valley MD generate business value from its technologies?
  According to its public updates, the company pursues value through licensing arrangements, product implementation with partners, and reselling of licensed products such as Agrarius™ within defined territories, rather than through direct large-scale manufacturing.
• What is Quicksome™ technology?
  Quicksome™ is described by the company as a patented liposomal oral formulation and delivery technology that uses proprietary formulations and stabilizing molecules to encapsulate active ingredients. It is designed for sublingual nutraceutical applications where enhanced efficacy, precise dosing, reduced variability, and dose sparing are important.
• What is Quicksol™ technology?
  Quicksol™ is a patented solubility formulation technology that, according to Mountain Valley MD, covers highly solubilized macrocyclic lactones. The company reports using Quicksol™ to create formulations such as Soluvec™ 1% for husbandry animals and aquatic species, with the goal of improving solubility, bioavailability, and stability.
• What is Agrarius™ and how is Mountain Valley MD involved?
  Agrarius™ is described as a certified organic agricultural plant signaling technology designed to be applied to crops to naturally increase yields, reduce fertilizer usage where desired, and increase resilience to pests and climate change. Mountain Valley MD holds an exclusive license to sell Agrarius™ in North America, Mexico, Central America, South America, and the Caribbean, and acts as a licensed product reseller.
• Which markets does Mountain Valley MD target with Agrarius™?
  The company reports that its exclusive Agrarius™ territory covers North America, Mexico, Central America, South America, and the Caribbean. It has disclosed business development and trial activities in regions such as Brazil, Colombia, Canada, and the United States, among others within this territory.
• How does the Performance Guarantee Program for Agrarius™ work?
  Mountain Valley MD describes a Performance Guarantee Program under which participating farming clients pay for Agrarius™ only if a minimum agreed performance threshold is achieved on their crops. The company and Agrarius Corp. share the performance risk, with payment obligations tied to meeting defined outcomes.
• What is Soluvec™ 1%?
  Soluvec™ 1% is a formulation created by applying the company’s Quicksol™ technology to ivermectin. Mountain Valley MD describes it as designed for broad administration across husbandry animals and aquatic species, and reports that it has licensed exclusive manufacturing and distribution rights for Soluvec™ 1% in Bangladesh to a partner in exchange for royalties.
• What is the “Mountains Of…” brand?
  “Mountains Of…” is a proprietary nutraceutical brand owned by Mountain Valley MD. The company states that it has obtained U.S. trademark protection for categories including Sleep, Energy, Relief, Libido, and Lean, and uses the brand to support GMP sample development and business development activities for Quicksome™-based products.
• Is Mountain Valley MD a mining company?
  Although an external classification lists the industry as gold ore mining, Mountain Valley MD’s own public disclosures consistently describe its operations in terms of patented oral and solubility technologies, nutraceutical products, and agricultural plant signaling technologies, not mineral extraction.